Victrex’s (VCT) “Sell” Rating Reiterated at UBS Group

Victrex (LON:VCT)‘s stock had its “sell” rating reiterated by research analysts at UBS Group in a research report issued on Monday,Digital Look reports. They currently have a GBX 575 price target on the stock. UBS Group’s price objective indicates a potential downside of 2.47% from the company’s current price.

A number of other analysts have also recently commented on VCT. Canaccord Genuity Group reiterated a “buy” rating and set a GBX 725 target price on shares of Victrex in a research report on Monday, April 13th. JPMorgan Chase & Co. decreased their target price on Victrex from GBX 725 to GBX 625 and set a “buy” rating for the company in a research report on Wednesday, March 18th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of GBX 720.83.

Victrex Trading Up 0.1%

LON VCT opened at GBX 589.54 on Monday. The firm’s fifty day moving average price is GBX 612.46 and its 200 day moving average price is GBX 644.88. Victrex has a 12 month low of GBX 515 and a 12 month high of GBX 882. The company has a debt-to-equity ratio of 11.30, a current ratio of 3.01 and a quick ratio of 1.99. The company has a market capitalization of £513.63 million, a price-to-earnings ratio of 18.54, a price-to-earnings-growth ratio of 1.92 and a beta of 0.75.

Victrex (LON:VCT) last announced its quarterly earnings results on Monday, May 11th. The company reported GBX 17.20 earnings per share for the quarter. Victrex had a net margin of 9.50% and a return on equity of 6.40%. The firm had revenue of £147.10 million during the quarter. On average, sell-side analysts expect that Victrex will post 73.1078905 earnings per share for the current fiscal year.

Victrex Company Profile

Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, automotive, aerospace, and electronics markets; and engages in trading activities.